Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 407

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 407
---
 currently do not meet the Round Lot Requirement. We have engaged a securities market advisory firm to assist with obtaining the requisite number of round lot stockholders to satisfy the Round Lot Requirement before the Business Combination is consummated.

The closing price of the Iris Class A Common Stock, Iris Units and Iris warrants on January 2, 2025, was $11.22, $10.82 and $0.03, respectively. As of , 2025 the record date for the Special Meeting, the most recent closing price for each Iris Class A Common Stock, Iris Unit and Iris warrant was $ , $ and $ , respectively.

Holders of the Iris Class A Common Stock, Iris Units and Iris warrants should obtain current market quotations for their securities. The market price of Iris’s securities could vary at any time before the Business Combination.

#### Holders
As of January 2, 2025, there was 1 holder of record of Iris Units, 3 holders of record of Iris Class A Common Stock and 3 holders of record of Iris Warrants.

#### Dividend Policy of Iris
Iris has not paid any cash dividends on Iris’s common stock to date and does not intend to pay cash dividends prior to the completion of the Business Combination. The payment of cash dividends in the future will be dependent upon Iris revenues and earnings, if any, capital requirements and general financial condition subsequent to completion of a business combination. The payment of any cash dividends subsequent to a business combination will be within the discretion of the ParentCo board of directors at such time (as described in more detail below). Further, if Iris incurs any indebtedness, its ability to declare dividends may be limited by restrictive covenants it may agree to in connection therewith.

#### Liminatus
There is no public market for Liminatus’s common stock.

Liminatus has never declared or paid any cash dividends on our capital stock. Liminatus currently intends to retain any future earnings and does not expect to pay any dividends in the foreseeable future. Future cash dividends, if any, will be at the discretion of the ParentCo Board, subject to applicable law, and will depend upon, among other things, Liminatus’s future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors the ParentCo Board may deem relevant.

<div align='center'>225</div>

TABLE OF CONTENTS

### LEGAL MATTERS
Holland & Knight LLP has passed upon the validity of the securities of ParentCo offered